Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharmaceuticals (Nasdaq: SHPH), a specialty pharmaceutical company focused on improving cancer radiation therapy outcomes, has completed a $4.25 million private placement with an accredited investor. The company issued 1,180,877 shares of common stock (or pre-funded warrants) at $3.60 per share, priced at-the-market under Nasdaq rules.
The net proceeds will be used for potential acquisitions, marketing, and general corporate purposes. WestPark Capital served as the exclusive placement agent. The company has agreed to file registration statements with the SEC for the resale of the shares and warrant shares.
Shuttle Pharmaceuticals (Nasdaq: SHPH), un'azienda farmaceutica specializzata focalizzata sul miglioramento dei risultati della radioterapia oncologica, ha completato un collocamento privato da 4,25 milioni di dollari con un investitore accreditato. La società ha emesso 1.180.877 azioni ordinarie (o warrant pre-finanziati) al prezzo di 3,60 dollari per azione, valutate al prezzo di mercato secondo le regole del Nasdaq.
I proventi netti saranno utilizzati per eventuali acquisizioni, attività di marketing e scopi societari generali. WestPark Capital ha agito come agente esclusivo per il collocamento. La società ha inoltre concordato di presentare dichiarazioni di registrazione alla SEC per la rivendita delle azioni e dei warrant.
Shuttle Pharmaceuticals (Nasdaq: SHPH), una compañía farmacéutica especializada enfocada en mejorar los resultados de la radioterapia contra el cáncer, ha completado una colocación privada de 4,25 millones de dólares con un inversor acreditado. La empresa emitió 1.180.877 acciones ordinarias (o warrants prefinanciados) a 3,60 dólares por acción, valoradas al precio de mercado según las normas del Nasdaq.
Los ingresos netos se destinarán a posibles adquisiciones, marketing y propósitos corporativos generales. WestPark Capital actuó como agente exclusivo de colocación. La empresa ha acordado presentar declaraciones de registro ante la SEC para la reventa de las acciones y los warrants.
Shuttle Pharmaceuticals (나스닥: SHPH)는 암 방사선 치료 결과 개선에 주력하는 전문 제약회사로, 공인 투자자와 함께 425만 달러 규모의 사모 발행을 완료했습니다. 회사는 나스닥 규정에 따라 시장가로 평가된 주당 3.60달러에 1,180,877주의 보통주(또는 선납 워런트)를 발행했습니다.
순수익금은 잠재적 인수, 마케팅 및 일반 기업 목적에 사용될 예정입니다. WestPark Capital이 독점 배정 대행사로 활동했습니다. 회사는 주식 및 워런트 주식의 재판매를 위해 SEC에 등록 서류를 제출하기로 합의했습니다.
Shuttle Pharmaceuticals (Nasdaq : SHPH), une société pharmaceutique spécialisée axée sur l'amélioration des résultats de la radiothérapie contre le cancer, a réalisé un placement privé de 4,25 millions de dollars auprès d'un investisseur accrédité. La société a émis 1 180 877 actions ordinaires (ou des bons de souscription préfinancés) au prix de 3,60 dollars par action, valorisées au prix du marché selon les règles du Nasdaq.
Les produits nets seront utilisés pour d'éventuelles acquisitions, le marketing et des fins générales d'entreprise. WestPark Capital a agi en tant qu'agent exclusif de placement. La société s'est engagée à déposer des déclarations d'enregistrement auprès de la SEC pour la revente des actions et des bons de souscription.
Shuttle Pharmaceuticals (Nasdaq: SHPH), ein auf die Verbesserung der Ergebnisse der Krebsstrahlentherapie spezialisiertes Pharmaunternehmen, hat eine Private Placement in Höhe von 4,25 Millionen US-Dollar mit einem akkreditierten Investor abgeschlossen. Das Unternehmen hat 1.180.877 Stammaktien (oder vorfinanzierte Warrants) zu einem Preis von 3,60 US-Dollar pro Aktie ausgegeben, bewertet zum Marktpreis gemäß den Nasdaq-Regeln.
Die Nettoerlöse werden für potenzielle Akquisitionen, Marketing und allgemeine Unternehmenszwecke verwendet. WestPark Capital fungierte als exklusiver Platzierungsagent. Das Unternehmen hat sich verpflichtet, bei der SEC Registrierungsunterlagen für den Wiederverkauf der Aktien und Warrants einzureichen.
- Secured $4.25 million in additional funding through private placement
- Strategic flexibility with funds allocated for potential acquisitions and marketing
- Placement priced at-the-market, indicating fair market value
- Potential dilution for existing shareholders with issuance of 1,180,877 new shares
- Securities currently not registered, limiting immediate tradability
Insights
Shuttle Pharma secured $4.25M in at-market financing, bolstering its capital position for potential acquisitions and operations.
Shuttle Pharmaceuticals has successfully closed a
The stated use of proceeds – potential acquisitions, marketing, and general corporate purposes – suggests a strategic pivot beyond pure R&D activities. For a discovery and development stage company, the explicit mention of potential acquisitions indicates management may be looking to accelerate growth through inorganic means rather than relying solely on internal pipeline development, which typically requires more substantial capital and longer timelines.
WestPark Capital's involvement as exclusive placement agent lends institutional credibility to the transaction. The at-market pricing is particularly notable, as it indicates investor willingness to participate without demanding the significant discounts often seen in biotech private placements. This suggests reasonable confidence in the company's near-term prospects despite being in early development stages.
The registration rights agreement with investors provides liquidity assurance, though the current unregistered status of these securities means they cannot be immediately resold, potentially reducing near-term selling pressure. While this financing provides operational runway, investors should note that development-stage pharmaceutical companies typically require multiple capital raises before reaching profitability.
GAITHERSBURG, Md., June 24, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of
In connection with the offering, the Company issued 1,180,877 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) at a purchase price of
WestPark Capital, Inc. acted as the exclusive placement agent in connection with the offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the "SEC").
The securities described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Shuttle Pharmaceuticals
Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (“RT”). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Cautionary Note Regarding Forward Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company, and use of proceeds. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact
Shuttle Pharmaceuticals
Chris Cooper
Chief Executive Officer
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
shph@lythampartners.com
FAQ
What is the size and price of Shuttle Pharmaceuticals (SHPH) private placement in June 2025?
How will Shuttle Pharmaceuticals (SHPH) use the proceeds from the private placement?
Who acted as the placement agent for Shuttle Pharmaceuticals' (SHPH) private placement?
Will the new Shuttle Pharmaceuticals (SHPH) shares be registered with the SEC?
What is Shuttle Pharmaceuticals' (SHPH) main business focus?
